CymaBay: Redefining Expectations for PBC Patients: Analyst Day on Seladelpar (MBX-8025)
About The Event
Join us for the CymaBay virtual Analyst Day, featuring a presentation from Key Opinion Leader Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD (Elson S. Floyd College of Medicine) who will discuss the current treatment landscape and future goals for treating patients with the autoimmune liver disease, Primary Biliary Cholangitis (PBC).
CymaBay’s seladelpar (MBX-8025), a potent, selective, orally active PPARδ agonist, will be presented as a potential treatment solution for patients suffering from PBC. Additionally, the CymaBay leadership team will discuss the unmet medical needs in the PBC landscape and seladelpar’s (MBX-8025) potential impact.
A live question and answer session will follow the formal presentations.